ACTIVE_NOT_RECRUITING

Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)

NCT05537701•Centre Hospitalier Universitaire de Liege

Summary

The primary objective is to describe eosinophil infiltration in resected (early stage) NSCLC. Secondary objectives are: * to investigate the correlation of T-Eos and B-Eos in the aforementioned patient population; * to investigate the correlation between T-Eos and overall \& disease-free survival; * to investigate the localization of T-Eos (periphery vs. center of the tumor lesions).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Resected, early stage NSCLC between 01-01-2015 and 30-04-2022 with available tumour tissue

Exclusion Criteria

•Inclusion in a clinical study contraindicating enrollment in the present study

Locations (1)

CHU de Liege

Liège, Belgium

Key Dates

Start Date

October 3, 2022

Primary Completion Date

March 31, 2027

Completion Date

March 31, 2027

Last Updated

January 16, 2024

Enrollment

316

ACTUAL participants

Conditions

Non-small Cell Lung Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITING

PHASE2/PHASE3